Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Looking for changes in lipid levels with knock out of ACADM (shACADM) (part II) (Study ST000819)

C18 NEGATIVE ION MODE (Analysis AN001300)

Metabolite	Structure	F1	F2	F3
CL 78:11; [M-2H](2-)@9.67	ME220248	1.62	0.77	0.61
PG 40:5; [M-H]-@5.62	ME220311	1.56	0.68	0.77
lysoPE 18:0; [M-H]-@2.40	ME220356	0.66	1.45	0.89
CL 62:1; [M-2H](2-)@5.51	ME220214	0.56	1.34	1.10
PE 34:4; [M-H]-@5.67	ME220271	0.52	1.44	1.05
PE 39:4; [M-H]-@6.99	ME220284	0.96	1.20	0.84
PS 34:2; [M-H]-@5.41	ME220340	0.96	1.17	0.87
PE 38:2; [M-H]-@7.44	ME220280	0.87	1.25	0.88
PS 38:6; [M-H]-@5.28	ME220349	0.90	1.19	0.92
plasmenyl-PE 42:6; [M-H]-@7.69	ME220378	0.98	1.11	0.92
PS 36:2; [M-H]-@5.93	ME220342	0.96	1.09	0.95
PS 40:1; [M-H]-@7.52	ME220350	0.86	1.16	0.97
PE 36:1; [M-H]-@7.35	ME220275	0.87	1.15	0.98
PE 37:4; [M-H]-@6.63	ME220279	0.88	1.14	0.97
PE 40:8; [M-H]-@5.85	ME220288	0.88	1.15	0.97
PE 37:1; [M-H]-@7.46	ME220277	0.89	1.11	1.00
PS 38:3; [M-H]-@6.24	ME220346	0.89	1.13	0.98
FFA(22:0)	ME220258	0.91	1.12	0.97
plasmenyl-PE 38:1; [M-H]-@8.11	ME220367	0.91	1.13	0.96
CL 74:1; [M-2H](2-)@6.58	ME220239	0.86	1.11	1.03
PS 36:1; [M-H]-@6.43	ME220341	0.85	1.10	1.05
PI 34:2; [M-H]-@5.31	ME220326	0.84	1.13	1.03
PI 36:1; [M-H]-@6.35	ME220327	0.84	1.15	1.01
PE 34:3; [M-H]-@5.91	ME220270	0.64	1.19	1.17
PE 35:0; [M-H]-@7.44	ME220272	0.75	1.28	0.97
PE 35:3; [M-H]-@6.14	ME220273	0.76	1.22	1.02
plasmenyl-PE 38:0; [M-H]-@8.50	ME220366	0.75	1.21	1.04
PS 38:4; [M-H]-@5.94	ME220347	0.75	1.21	1.03
CL 74:11; [M-2H](2-)@5.57	ME220240	0.73	1.12	1.16
PE 33:1; [M-H]-@6.51	ME220269	0.76	1.12	1.13
PS 34:1; [M-H]-@5.89	ME220339	0.77	1.15	1.08
PS 38:2; [M-H]-@6.56	ME220345	0.80	1.14	1.06
PS 40:6; [M-H]-@5.89	ME220354	0.81	1.11	1.08
FFA(20:2)	ME220256	1.08	0.88	1.05
PG 34:1; [M-H]-@5.84	ME220296	1.03	0.92	1.06
PS 38:5; [M-H]-@5.48	ME220348	1.03	0.92	1.04
CL 68:1; [M-2H](2-)@9.81	ME220221	1.05	0.92	1.03
PG 44:12; [M-H]-@4.58	ME220321	1.07	0.90	1.03
CL 68:5; [M-2H](2-)@9.02	ME220225	1.01	0.90	1.09
FFA(24:1)	ME220263	1.00	0.92	1.07
FFA(18:1)	ME220252	0.98	0.96	1.06
PI 32:0; [M-H]-@5.63	ME220323	0.97	0.96	1.07
PG 34:2; [M-H]-@5.25	ME220297	0.99	0.95	1.05
PS 40:2; [M-H]-@7.04	ME220351	1.01	0.95	1.04
PS 40:5; [M-H]-@6.08	ME220353	1.01	0.95	1.04
PE 39:6; [M-H]-@6.54	ME220286	0.93	0.99	1.07
plasmenyl-PE 38:4; [M-H]-@7.17	ME220370	0.92	1.01	1.06
plasmenyl-PE 40:4; [M-H]-@7.60	ME220374	0.92	1.03	1.05
PG 38:4; [M-H]-@5.53	ME220307	0.89	1.06	1.05
PI 38:4; [M-H]-@5.81	ME220332	0.94	1.04	1.02
plasmenyl-PE 36:2; [M-H]-@7.24	ME220365	0.92	1.06	1.02
PI 38:3; [M-H]-@6.15	ME220331	0.99	1.02	0.99
plasmenyl-PE 36:0; [M-H]-@8.08	ME220364	0.99	1.01	1.00
CL 66:1; [M-2H](2-)@9.58	ME220216	0.98	1.01	1.01
PE 42:7; [M-H]-@6.69	ME220290	0.98	1.02	1.00
PE 37:3; [M-H]-@6.90	ME220278	1.02	0.96	1.02
CL 72:5; [M-2H](2-)@9.52	ME220235	1.00	0.98	1.02
PI 34:1; [M-H]-@5.73	ME220325	1.01	0.97	1.02
PS 40:4; [M-H]-@6.44	ME220352	1.00	0.99	1.00
CL 74:5; [M-2H](2-)@9.74	ME220241	0.98	0.99	1.02
PG 36:0; [M-H]-@6.95	ME220299	0.99	0.99	1.02
plasmenyl-PE 38:3; [M-H]-@7.44	ME220369	1.05	1.02	0.93
FFA(16:0)	ME220250	1.04	1.03	0.94
FFA(18:0)	ME220251	1.04	1.03	0.93
FFA(20:0)	ME220254	1.00	1.05	0.95
PE 33:0; [M-H]-@6.96	ME220268	0.98	1.04	0.98
PI 40:5; [M-H]-@5.98	ME220336	0.99	1.04	0.97
PE 36:0; [M-H]-@7.77	ME220274	1.06	1.09	0.84
PI 40:6; [M-H]-@5.82	ME220337	1.03	1.07	0.89
PS 36:3; [M-H]-@5.65	ME220343	1.12	1.03	0.84
plasmenyl-PE 31:0; [M-H]-@6.62	ME220362	1.09	1.02	0.89
plasmenyl-PE 42:5; [M-H]-@7.81	ME220377	1.07	1.05	0.88
CL 72:7; [M-2H](2-)@9.18	ME220237	1.10	0.90	1.00
PG 38:3; [M-H]-@5.87	ME220306	1.10	0.91	0.99
PG 38:5; [M-H]-@5.11	ME220308	1.13	0.88	0.99
plasmenyl-PE 38:5; [M-H]-@6.70	ME220371	1.14	0.85	1.01
lysoPE 20:4; [M-H]-@1.29	ME220357	1.19	0.91	0.90
CL 70:2; [M-2H](2-)@9.83	ME220227	1.17	0.92	0.91
plasmenyl-PE 33:0; [M-H]-@7.17	ME220363	1.16	0.92	0.91
CL 72:4; [M-2H](2-)@9.69	ME220234	1.17	0.91	0.92
CL 68:2; [M-2H](2-)@9.57	ME220222	1.16	0.91	0.93
CL 70:3; [M-2H](2-)@9.61	ME220228	1.16	0.91	0.93
CL 72:6; [M-2H](2-)@9.32	ME220236	1.08	0.96	0.96
FFA(22:1)	ME220259	1.08	0.94	0.98
FFA(24:0)	ME220262	1.12	0.97	0.90
CL 70:6; [M-2H](2-)@9.10	ME220231	1.11	0.96	0.93
CL 72:8; [M-2H](2-)@8.97	ME220238	1.11	0.95	0.93
PE 40:4; [M-H]-@7.27	ME220287	1.09	0.99	0.92
plasmenyl-PE 42:4; [M-H]-@8.00	ME220376	1.10	0.98	0.92
CL 72:3; [M-2H](2-)@9.86	ME220233	1.08	0.98	0.94
FFA(18:2)	ME220253	1.10	0.97	0.93
PE 39:3; [M-H]-@7.28	ME220283	1.09	0.97	0.94
CL 70:1; [M-2H](2-)@6.11	ME220226	0.88	1.02	1.10
PE 38:3; [M-H]-@7.17	ME220281	0.83	1.08	1.09
plasmenyl-PE 38:2; [M-H]-@7.74	ME220368	0.83	1.06	1.11
plasmenyl-PE 40:1; [M-H]-@8.54	ME220373	0.85	1.05	1.10
FFA(22:3)	ME220261	0.89	0.98	1.13
plasmenyl-PE 40:6; [M-H]-@7.12	ME220375	0.89	0.98	1.13
PI 36:3; [M-H]-@5.51	ME220329	0.90	0.95	1.15
PI 38:5; [M-H]-@5.46	ME220333	0.88	0.95	1.17
CL 74:7; [M-2H](2-)@6.01	ME220244	0.83	0.99	1.18
PG 38:2; [M-H]-@6.63	ME220305	0.84	0.98	1.19
CL 70:5; [M-2H](2-)@9.28	ME220230	0.85	1.02	1.14
PG 36:2; [M-H]-@5.70	ME220301	0.82	1.03	1.15
PG 36:1; [M-H]-@6.50	ME220300	0.76	0.99	1.24
PE 36:6; [M-H]-@5.47	ME220276	0.77	1.04	1.19
PS 32:1; [M-H]-@5.25	ME220338	0.73	1.05	1.22
CL 78:13; [M-2H](2-)@5.71	ME220249	0.83	0.94	1.24
PE 32:0; [M-H]-@6.67	ME220266	0.76	0.93	1.31
PI 32:1; [M-H]-@5.15	ME220324	0.73	0.95	1.32
CL 64:1; [M-2H](2-)@9.34	ME220215	0.91	0.79	1.30
PS 42:1; [M-H]-@8.04	ME220355	0.91	0.77	1.32
FFA(20:4) Arachidonic acid	ME220257	1.01	0.72	1.26
PG 33:1; [M-H]-@5.62	ME220295	1.06	0.73	1.21
PG 32:0; [M-H]-@5.80	ME220292	1.06	0.83	1.11
lysoPE 20:5; [M-H]-@1.08	ME220358	1.04	0.83	1.13
CL 66:2; [M-2H](2-)@9.39	ME220217	1.03	0.83	1.14
FFA(24:3)	ME220265	1.04	0.82	1.14
plasmenyl-PE 38:6; [M-H]-@6.50	ME220372	1.13	0.76	1.10
CL 68:4; [M-2H](2-)@9.22	ME220224	1.08	0.84	1.08
PG 38:7; [M-H]-@4.48	ME220310	1.12	0.80	1.08
PG 42:10; [M-H]-@4.63	ME220315	1.10	0.81	1.09
CL 74:6; [M-2H](2-)@9.57	ME220242	0.95	0.94	1.11
PE 42:4; [M-H]-@7.73	ME220289	0.94	0.94	1.12
FFA(20:1)	ME220255	0.97	0.92	1.11
PG 42:9; [M-H]-@4.90	ME220318	0.96	0.92	1.12
PG 36:5; [M-H]-@4.52	ME220304	1.00	0.84	1.16
CL 68:3; [M-2H](2-)@9.44	ME220223	0.96	0.89	1.16
FFA(22:2)	ME220260	0.99	0.88	1.13
CL 70:4; [M-2H](2-)@9.47	ME220229	0.98	0.88	1.14
PE 39:5; [M-H]-@6.60	ME220285	0.98	0.88	1.14
PS 36:4; [M-H]-@5.38	ME220344	0.97	0.80	1.23
PG 32:1; [M-H]-@5.23	ME220293	0.97	0.85	1.19
CL 66:3; [M-2H](2-)@9.19	ME220219	0.97	0.83	1.20
PI 36:4; [M-H]-@5.28	ME220330	0.96	0.83	1.21
PI 40:4; [M-H]-@6.34	ME220335	0.90	0.85	1.25
CL 76:8; [M-2H](2-)@9.44	ME220246	0.93	0.90	1.17
PG 34:3; [M-H]-@4.78	ME220298	0.92	0.92	1.16
PE 38:7; [M-H]-@5.69	ME220282	0.91	0.87	1.21
PG 40:7; [M-H]-@5.05	ME220313	0.93	0.88	1.20
CL 72:2; [M-2H](2-)@10.02	ME220232	1.28	1.00	0.72
plasmenyl-PE 30:0; [M-H]-@6.40	ME220361	1.21	0.96	0.83
PG 33:0; [M-H]-@6.12	ME220294	1.23	0.88	0.89
PI 36:2; [M-H]-@5.91	ME220328	1.22	0.90	0.89
CL 74:7; [M-2H](2-)@9.40	ME220243	1.25	0.89	0.86
lysoPE 22:6; [M-H]-@1.24	ME220360	1.22	0.91	0.86
PG 36:4; [M-H]-@4.89	ME220303	1.29	0.85	0.86
PG 40:8; [M-H]-@4.72	ME220314	1.26	0.85	0.89
PG 40:6; [M-H]-@5.35	ME220312	1.33	0.84	0.82
CL 66:4; [M-2H](2-)@8.96	ME220220	1.30	0.77	0.93
PG 44:9; [M-H]-@5.42	ME220322	1.32	0.80	0.88
FFA(24:2)	ME220264	1.30	0.72	0.98
PG 42:8; [M-H]-@5.32	ME220317	1.25	0.71	1.04
lysoPE 22:5; [M-H]-@1.48	ME220359	1.21	0.83	0.95
PG 36:3; [M-H]-@5.28	ME220302	1.23	0.83	0.94
CL 76:9; [M-2H](2-)@9.30	ME220247	1.18	0.77	1.05
PE 32:0; [M-H]-@5.86	ME220267	1.19	0.79	1.02
PG 38:6; [M-H]-@4.81	ME220309	1.19	0.81	1.00
PG 42:7; [M-H]-@5.48	ME220316	1.13	0.59	1.28
PG 44:10; [M-H]-@5.16	ME220319	1.38	0.60	1.03
PE 44:4; [M-H]-@8.49	ME220291	1.37	0.57	1.07
PG 44:11; [M-H]-@4.92	ME220320	1.40	0.53	1.08
CL 66:3; [M-2H](2-)@5.66	ME220218	0.45	1.17	1.38
CL 74:9; [M-2H](2-)@5.64	ME220245	0.70	0.87	1.43
PI 38:6; [M-H]-@5.14	ME220334	0.80	0.82	1.38

Factors:

F1	Transduced with:shACADM4
F2	Transduced with:shACADM6
F3	Transduced with:shACADMscr

Data matrix